Imagen de Portada

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Xing Bai, Ziqi Sui, Yunmeng Nie
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
por: Chia‐Chih Kuo, et al.
Publicado: (2025)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
por: Mingsi Zhang, et al.
Publicado: (2024)

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease
por: Derek D. Satre, et al.
Publicado: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
por: Xinglin Li, et al.
Publicado: (2026)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
por: Raj Vuppalanchi, et al.
Publicado: (2025)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
por: Junbin Yan, et al.
Publicado: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
por: Ryan Yanzhe Lim, et al.
Publicado: (2026)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
por: Glenn Jun Kit Ho, et al.
Publicado: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
por: Pojsakorn Danpanichkul, et al.
Publicado: (2025)

Disparities in Alcohol‐Associated Liver Disease Hospital Encounters Amongst a Texas‐Based Cohort of Patients
por: Thomas G. Cotter, et al.
Publicado: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
por: Ewan Forrest, et al.
Publicado: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
por: Shupeng Zhao, et al.
Publicado: (2025)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
por: Stine Johansen, et al.
Publicado: (2026)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
por: Yee Hui Yeo, et al.
Publicado: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis
por: Luke D. Tyson, et al.
Publicado: (2026)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Stergios A. Polyzos, et al.
Publicado: (2024)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
por: Chunlong Liu, et al.
Publicado: (2025)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
por: Andrew W. Nguyen, et al.
Publicado: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
por: Muhammad Osama, et al.
Publicado: (2024)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
por: Kaleb Tesfai, et al.
Publicado: (2026)

Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure
por: Charlotte Mouliade, et al.
Publicado: (2025)

Alcohol‐Attributable Cancer: Update From the Global Burden of Disease 2021 Study
por: Pojsakorn Danpanichkul, et al.
Publicado: (2025)

Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis
por: Mushfiqur R. Siddique, et al.
Publicado: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
por: Rong‐Xiang Ng, et al.
Publicado: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
por: Nina Dominik, et al.
Publicado: (2024)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
por: C. C. Mark Cheah, et al.
Publicado: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
por: Xiao‐Dong Zhou, et al.
Publicado: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
por: Qiong Yi, et al.
Publicado: (2024)

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence
por: Priyadarshini Zula, et al.
Publicado: (2026)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
por: Juan Macias, et al.
Publicado: (2025)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
por: Finlay Macrae
Publicado: (2025)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
por: Muhammad Abubakr, et al.
Publicado: (2025)

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
por: Joëlle St‐Pierre, et al.
Publicado: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
por: Eunice Yewon Lee, et al.
Publicado: (2024)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
por: Leyu Zhou, et al.
Publicado: (2024)